To confirm that the VAR2+, CD45− cells detected in the patient blood samples were indeed glioma-derived CTCs, we performed targeted whole exome sequencing (WES) searching for glioma relevant mutations. This evidence concerns the gene PTPRC and central nervous system cancer.